CASE REPORT

Amniocentesis in the HIV-infected pregnant woman: Is there still cause for concern in the era of combination antiretroviral therapy?

Nisha Andany BSc MD1, Michelle Letchumanan BSc2, Lise Bondy BSc MD1, Kellie Murphy MD MSc FRCS3, Mona R Loutfy MD MPH FRCP1,4

The current standard of care in Canadian obstetrical practice is to offer pregnant women the opportunity for prenatal investigation to diagnose congenital abnormalities. Prenatal amniocentesis is Canada’s most commonly practiced invasive procedure for the diagnosis of chromosomal and single gene disorders. The potential risk of intrapartum HIV transmission during amniocentesis raises several ethical concerns and limits the availability of prenatal genetic testing for HIV-positive pregnant women. Complete virological suppression with antiretroviral therapy may alleviate the risk of mother-to-child transmission during amniocentesis and increase accessibility of this important diagnostic tool in the HIV-positive population. The present report describes a case involving a 32-year-old HIV-positive pregnant woman whose plasma viral load was undetectable on antiretroviral therapy; she underwent successful prenatal amniocentesis without transmission of HIV to her infant.

Key Words: Amniocentesis; Antiretroviral therapy; HIV; Undetectable viral load

The goal of equitable HIV management is to provide HIV-positive pregnant women with the same standard of obstetrical care that is available to the general population, including access to prenatal screening and diagnostic procedures. Mid-trimester amniocentesis is the most commonly used invasive procedure during pregnancy for the diagnosis of genetic and chromosomal abnormalities (1). Traditionally, invasive procedures in pregnancy have been contraindicated in HIV-positive women due to concerns that there may be an increased risk of viral transmission to the fetus; this increased risk is believed to be associated with procedure-associated fetal-placental contact and intra-amniotic bleeding (2-5). In 2003, the Society of Obstetricians and Gynaecologists of Canada (SOGC) issued guidelines for clinical counselling on prenatal amniocentesis in HIV-positive women; these guidelines recommend that every alternative be exhausted before considering amniocentesis in this patient population (6). However, the concern regarding increased risk of vertical transmission associated with amniocentesis is based on studies that were conducted before the use of combination antiretroviral therapy (ART) in pregnancy. The availability and effectiveness of combination therapy has had dramatic implications for pregnancy in the HIV-positive population. With a triple ART regimen, the risk of mother-to-child transmission has been reduced from 15% to 40% to approximately 1% (3,7). Consequently, a significantly higher proportion of HIV-infected women are choosing to become pregnant (8), and equitable access to high-quality obstetrical care, including prenatal diagnostic tests, becomes an important consideration. There are data to suggest that mid-trimester amniocentesis, in the era of effective ART, does not result in an increased risk of vertical transmission (9-13). However, the Canadian guidelines have not been updated to reflect these findings and may pose a barrier to optimal prenatal management for the HIV-infected pregnant population. In the present report, we discuss a case involving a 32-year-old HIV-positive woman who successfully underwent prenatal amniocentesis without transmission of the virus to her infant.

CASE PRESENTATION

A 32-year-old woman of Ugandan descent was diagnosed with HIV in 2003. Method of transmission was heterosexual intercourse and she was diagnosed based on immigration testing. Her baseline CD4 count was 120 cells/mm$^3$ and viral load (VL) was 53,113 copies/mL. She was diagnosed based on immigration testing. Her baseline CD4 count was 120 cells/mm$^3$ and viral load (VL) was 53,113 copies/mL. She was initially started on therapy with abacavir (ABC) (300 mg twice daily), lamivudine (3TC) (150 mg twice daily) and efavirenz (600 mg once daily) in 2003. She was unable to tolerate efavirenz and her antiretroviral regimen was subsequently changed to ABC/3TC and lopinavir/ritonavir (LPV/r, Kaletra) (three capsules, 400 mg/100 mg twice daily). With this regimen, she achieved and maintained an undetectable VL (<50 copies/mL) and had a CD4 count of approximately 380 cells/mm$^3$. Her medical history was otherwise significant for malaria in 2002, sickle cell trait and previous hepatitis B virus (HBV)
infected mothers; however, HBV DNA has not been detected, sug-
gregated to 5% to 15% (3). Hepatitis B surface antigen has been
HBeAg positive (3,6). With prophylaxis, transmission risk can be
highly variable, ranging from 10% to 15% in those who are hepatitis
in the diagnosis of sickle cell disease in the fetus. The patient and her partner elected to continue the
At 15 weeks, the patient reported an intolerance to LPV/r, mainly
nausea and diarrhea; this resulted in a substitution from LPR/r to
saquinavir and ritonavir (500 mg/100 mg twice daily); her ABC/3TC
were continued without any adverse effects. Additional medications
during the pregnancy included a maternal vitamin (Materna, Pfizer
Consumer Healthcare, Canada), calcium, terbinafine hydrochloride
and Rho(D) Immune Globulin (Rhogam, Ortho-Chemical Diagnostics,
USA). The patient reported regular adherence to treatment.
Throughout the pregnancy, her CD4 count was maintained at approxi-
mately 380 cells/mm³ and VL remained undetectable. At 35 weeks' gesta-
tional age, the patient developed pre-eclampsia and HELLP syn-
drome; she underwent Caesarean section with the use of intravenous
sidovudine (azidothymidine [AZT]) during the periperoiptive period.
She delivered a healthy female infant. The infant was referred to the
Hospital for Sick Children (Toronto, Ontario) for follow up and
underwent serial HIV testing as per protocol (HIV DNA polymerase
chain reaction testing at zero, one and two months, ELISA at 18 months), all of which were negative. Aside from the diagnosis of
sickle cell disease, the child is healthy and has experienced no other medical conditions.

DISCUSSION

The present report provides a Canadian perspective of an HIV-positive
woman who successfully underwent amniocentesis for prenatal diag-
nosis without vertical transmission. Prenatal mid-trimester amniocen-
tesis is at the forefront of obstetrical practice for the diagnosis of
chromosomal and single gene defects. The procedure involves sam-
ping of amniotic fluid via needle puncture of the uterine wall and is
traditionally offered to pregnant women who are at higher risk of hav-
ing a child with a congenital abnormality; this includes women with
abnormal ultrasounds or noninvasive screening tests, or those who
have a predisposition to congenital abnormalities (advanced maternal age, family history of congenital birth defect, prenatal infection, sub-
stance use, etc) (1). Amniocentesis can also be used later in pregnancy for
the diagnosis of prenatal infection or to assess fetal lung maturity
(15).

There are several risks associated with amniocentesis including spontaneous abortion and fetal demise, premature rupture of mem-
branes, chorioamnionitis, fetal-maternal bleeding and intra-amniotic
bleeding (1,3,4). There are concerns that exposure to maternal blood
during amniocentesis may increase the risk of intrauterine transmis-
sion of several blood-borne viruses, especially if a transplacental
approach is used (3,5). The risk of perinatal HBV transmission is
highly variable, ranging from 10% to 15% in those who are hepatitis B e antigen (HBeAg) negative to up to 70% to 90% in those who are
HBeAg positive (3,6). With prophylaxis, transmission risk can be
reduced to 5% to 15% (3). Hepatitis B surface antigen has been
detected in the amniotic and cord blood of infants with HBV-
infected mothers; however, HBV DNA has not been detected, sug-
gesting that the complete virus does not cross the placenta (16,17).
There are few studies that have examined HBV transmission with
amniocentesis, but available data indicate that in mothers who are
HBeAg negative, the risk is equivalent to those not undergoing
amniocentesis (17,18). A positive HBeAg status can increase this
transmission risk up to 30% (18). The natural rate of hepatitis C (HCV) vertical transmission ranges from ≤1% in women who are
HCV RNA negative, to 5% in those who are HCV RNA positive; HIV coinfection can further increase the risk up to 20% (3). There
are very little data with respect to HCV transmission during amnio-
centesis. In one study of 22 HCV-infected women (16 HCV RNA
positive) who underwent a second-trimester amniocentesis, HCV RNA
was detected in the amniotic fluid of one infant but the child
subsequently tested negative for infection (19). There were no instances of vertical transmission, but only 10 infants were tested.
However, no definitive conclusions can be drawn from these data.

For HBV and HCV, the SOGC suggests that the risk of transmission
with amniocentesis is low and that these procedures can likely be
safely performed; however, HBeAg status of the mother may influence
the decision to perform the procedure given the increased risk in those who are HBeAg positive (6).

The vast majority of worldwide pediatric HIV infection occurs
perinatally. The risk of vertical HIV transmission in pregnancy ranges from 15% to 40% when ART is not used; approximately 30%
occur in the antenatal period and 70% occurs in the intrapartum
period (3,7,20). HIV has been detected in the amniotic fluid of preg-
nant women, but this does not appear to occur frequently. In a case
report involving an HIV-infected woman who underwent amnio-
centesis in the third trimester of pregnancy, HIV was isolated via viral
culture from the amniotic fluid. This patient was not on ART and no
information is available regarding the HIV-status of the infant (21).
In a subsequent study of women undergoing amniocentesis during
pregnancy (n=29) and those who had amniotic fluid collected at
delivery (n=38), HIV RNA was not detected in any of the amniotic
fluid samples (13). Eighty-four per cent of women in this study were
on ART. Similarly, a study of amniotic fluid from 23 HIV-infected
women taken at elective Caesarean section did not show the pres-
ence of HIV RNA (20). An examination of 40 HIV-infected women
who had amniotic fluid sampled during elective Caesarean section
revealed HIV RNA in three samples (7.5%); in each case, VL in the
amniotic fluid was <100 copies/mL, the mother was on ART with a
suppressed plasma VL and all three neonates had undetectable
plasma VL at birth (22). These data suggest that while HIV RNA
may infrequently be present in amniotic fluid, this does not necessar-
ily translate to fetal infection.

Previous studies have suggested higher rates of intrauterine viral
transmission when amniocentesis is performed in HIV-positive
women (2,15,23). Mandelbrot et al (2) reported data on a cohort of
68 HIV-infected women who underwent invasive procedures during
pregnancy between 1985 and 1993; of these 68 procedures, 13 were
amniocenteses and 26 were amniocentesis (both considered needling
procedures). Only 5.5% of the total study population received ante-
natal zidovudine (AZT) and the HIV transmission rate among
women who underwent an invasive needling procedure was 36%,
compared with 18.5% in those that did not have any procedure dur-
ing pregnancy (OR 2.08) (2). Similarly, HIV transmission occurred
in six of 15 infants born to HIV-positive mothers who underwent
amniocentesis during the third trimester (OR 4.10) (15). Furthermore,
in a study involving 196 HIV-infected women who were on AZT
monotherapy in pregnancy, vertical transmission was associated with any condition or procedure that increased the risk of
fetal-maternal bleeding, including amniocentesis (23). These data
have prompted clinicians to be cautious about counselling HIV-
positive women toward amniocentesis. The SOGC guidelines for the
use of amniocentesis in women with HIV, while recognizing that
data regarding transmission risk were sparse and that the effect
of combination therapy is unknown, suggest that every effort be
made to avoid performing amniocentesis in HIV-infected pregnant
women (6).
It is important to note that the aforementioned studies were conducted before the use of combination therapy. The introduction of ART has had a tremendous impact on HIV-associated morbidity and mortality. With the use of combination therapy, in addition to safe mode of delivery and avoidance of breastfeeding, the risk of mother-to-child HIV transmission can now be reduced to approximately 1% (7). The effectiveness of combination ART in preventing vertical transmission is related to viral suppression; the most important predictor of transmission is maternal VL and women with VL <1000 copies/mL have a minimal risk of transmitting HIV to their infants (24). Antiretroviral agents can also penetrate the amniotic fluid to different degrees. An analysis of six women on ART with amniotic fluid samples collected at delivery demonstrated that nucleoside reverse transcriptase inhibitor levels were higher than maternal values indicating poor penetration (LPV and ritonavir 96% lower than maternal levels); nevirapine concentration was approximately 47% lower than maternal blood levels and protease inhibitor (PI) levels were substantially lower than maternal values indicating poor penetration (158 times higher); tenofovir 158 times higher); nevirapine concentration was approximately 47% lower than maternal blood levels and protease inhibitor (PI) levels were substantially lower than maternal values indicating poor penetration (LPV and ritonavir 96% lower than maternal levels) (25). The low concentration of PIs in amniotic fluid was also demonstrated in a study of 24 women who received ART in pregnancy; PI concentrations were below the limit of detection in 10 of 16 fluid samples for nelfinavir, one of three samples with indinavir, and four of four samples for ritonavir (26). However, despite variations in amniotic fluid penetration, combination therapy, with or without PIs, continues to substantially reduce the risk of vertical transmission and PI-based regimens are considered to be first line by the United States (US) Department of Health and Human Services for the prevention of mother-to-child transmission (7). The utility of measuring antiretroviral levels in amniotic fluid is unclear and levels were not measured in our patient.

Lower rates of vertical transmission associated with amniocentesis have emerged in the era of effective ART (9-13). In a study involving 366 HIV-infected pregnant women, risk of vertical transmission was compared between two groups undergoing amniocentesis: those who underwent amniocentesis before 1997 (group ‘a’ [n=11]), and those who underwent amniocentesis after 1997 and just before delivery (group ‘b’ [n=18]). The rate of HIV transmission was 30% (three of 10) in women who had undergone amniocentesis before 1997, compared with 16.2% in those who did not undergo the procedure; of the three cases of transmission, two occurred in women not on therapy and one in a woman with a CD4 count <200 cells/μm³ (13). Of all women who underwent amniocentesis after 1997, rates of transmission did not differ from those who did not undergo the procedure (13). A retrospective review of 60 infants born to mothers who underwent amniocentesis in pregnancy (84% on ART) found that the rate of transmission (3.3%) was no different from the group who did not undergo amniocentesis (12). Coll et al (11) reported a study involving 116 HIV-infected pregnant women in which 10 women underwent amniocentesis. The median gestational age at the time of the procedure was 16.5 weeks and 70% of women had an undetectable VL; two pregnancies resulted in fetal demise and two women elected for pregnancy termination due to detection of a congenital abnormality. Of the six viable infants, there were no instances of vertical transmission (11). Similarly, Ekoukou et al (10) studied 11 women who underwent amniocentesis during pregnancy while on combination ART. There were two cases of fetal anomaly leading to termination of pregnancy and, of the nine live-born infants, none tested positive for HIV infection (10). Finally, in a study from the French Perinatal Cohort (9), 166 HIV-infected women underwent amniocentesis from 1995 to 2006. At the time of the procedure, median gestational age was 20 weeks and 78.9% of women were on ART (71.8% on combination therapy). There were 157 live births; the rate of pregnancy termination was higher in the group of women who had amniocentesis performed. The overall rate of transmission was 16.2%. There was a trend toward higher rates of transmission in women not on ART (25%), as well as in those on AZT monotherapy (6.1%) or dual ART (3.3%); there was no vertical transmission among the 81 pregnancies in which the mother was being treated with combination ART (9). Despite the apparent safety of performing amniocentesis in HIV-infected pregnant women in the era of combination therapy and VL suppression, the Canadian guidelines have not been updated to reflect these findings. This is in contrast to other regional guidelines for the management of HIV in pregnancy (Table 1). The US Department of Health and Human Services “Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States” were modified in 2010. The 2009 guidelines noted that amniocentesis had been found to increase risk of vertical transmission in some studies, but did recognize that these studies had not been performed in the era of potent ART (27). In the 2010 to 2012 guidelines, these recommendations were updated to recognize the lower risk of transmission with combination therapy (7); they caution that while an increased risk of transmission cannot be completely ruled out, antiretroviral therapy can be performed, when indicated, after the initiation of effective ART and ideally once VL is suppressed. If the VL is detectable, expert consultation is suggested. The British HIV

### TABLE 1

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SOGC: In HIV-positive women all noninvasive screening tools should be used before considering amniocentesis. Given the significant elevation in vertical transmission described, efforts should be made to avoid amniocentesis in HIV-positive women.</td>
<td>In women on effective ART, no perinatal transmissions have been reported after amniocentesis, but a small risk of transmission cannot be ruled out. If amniocentesis is indicated in HIV-infected women, it should be performed only after the initiation of effective ART regimen and, if possible, when HIV RNA levels are undetectable.</td>
<td>Invasive prenatal diagnostic testing should not be performed until after HIV status is known and should ideally be delayed until VL &lt;50 copies/mL. Limited data suggests that amniocentesis is safe when on ART; if the patient is not on treatment and amniocentesis cannot be delayed, ART should be commenced and should include raltegravir; a single dose of nevirapine should be used before the procedure.</td>
<td>No mention of invasive procedures in pregnancy.</td>
</tr>
<tr>
<td>CCG: Amniocentesis and chorionic vilius sampling have been implicated in vertical transmission but there are no data regarding the risk associated with these procedures. It is generally recommended that HIV-positive pregnant women not undergo these procedures unless the benefits outweigh the risks.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ART Antiretroviral therapy; CCG Canadian Consensus Guidelines for the management of HIV positive pregnant women and their offspring; SOGC Society of Obstetricians/Gynecologists of Canada; UK United Kingdom; VL Viral load.
Association has issued perinatal guidelines since 2001; while the language has been updated with each successive version, all of them maintain that if amniocentesis is indicated, the transplacental approach should be avoided and periprocedural ART may be required (28).

There are no available data to direct Canadian guidelines with regard to performing amniocentesis when the test is indicated, including information on whether rates of amniocentesis in HIV-infected pregnant women in Canada have increased with the use of combination therapy. Studies from Europe indicate that rates of amniocentesis are increasing in the HIV-infected population. One Italian study noted that rates of amniocentesis increased from 4% in 1997 to 14% in 2003 (12). Data from the French Perinatal cohort similarly demonstrated that rates increased from 0.8% before 1994 to 4.7% in 2005 (9). An additional French study conducted between 2001 and 2006 reported that 32.4% of women with an indication for amniocentesis underwent the procedure. The procedure was only performed in women on triple ART with a suppressed VL and CD4 count >200 cells/mm3 and there was no reported viral transmission (10).

Combination ART has completely revolutionized HIV medicine and has decreased the risk of mother-to-child transmission to ≤1%. Consequently, HIV-infected women can have successful pregnancies and more of them are choosing to become pregnant. It is important that HIV-positive women have access to the same standard of antenatal care as the general population. While noninvasive screening methods, such as integrated prenatal screening and ultrasounds, can provide a wealth of information, some women will have indications for invasive diagnostic tests due to abnormal test results or predispositions to genetic abnormalities. Mid-trimester amniocentesis is the most common prenatal invasive diagnostic procedure and available information indicates that the procedure can be performed safely without an increased risk of transmission in women with HIV. US and British guidelines have recognized this finding and suggest that after all non-invasive methods have been exhausted, amniocentesis may be conducted in women on combination therapy with a suppressed VL as long as the transplacental approach is avoided. However, barriers to accessing this service in Canada are rooted in evidence published during the pre-ART era. It will be important to consider these issues surrounding amniocentesis when the Canadian HIV pregnancy guidelines are updated.

CONFICT OF INTEREST: The authors declare that no competing interests exist. No financial support was required for the preparation of this manuscript.

REFERENCES


Submit your manuscripts at http://www.hindawi.com